Skip to main content
Clinical Trials/NCT04237467
NCT04237467
Recruiting
Not Applicable

Novel Evaluations of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men Compared to Age Group-Matched Transgender Women and Cisgender Adults

University of Colorado, Denver1 site in 1 country30 target enrollmentJanuary 29, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Transgender
Sponsor
University of Colorado, Denver
Enrollment
30
Locations
1
Primary Endpoint
Evaluation of endothelial function (flow-mediated dilation (FMD)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in older versus younger transgender men (people who were assigned female at birth but whose gender identity is male). Data will also be compared to those from age group-matched transgender women and cisgender women and men.

Registry
clinicaltrials.gov
Start Date
January 29, 2020
End Date
November 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 18-40 years old or 50-75 years old
  • Identify as a transgender woman
  • Have taken testosterone for at least one year
  • Currently taking testosterone parenterally (injections) or transdermally (patches or gels)

Exclusion Criteria

  • Don't identify as a transgender man
  • Not currently taking testosterone
  • Have been on testosterone for less than one year
  • History of hysterectomy/oophorectomy
  • Current tobacco smoker
  • Current illicit drug use
  • History of prior or active estrogen-dependent neoplasms
  • Acute liver or gallbladder disease
  • Venous thromboembolism
  • Hypertriglyceridemia \>500 mg/dL

Outcomes

Primary Outcomes

Evaluation of endothelial function (flow-mediated dilation (FMD)

Time Frame: Baseline

Brachial artery flow-mediated dilation (FMD), as measured by ultrasound.

Secondary Outcomes

  • Alcohol use(Baseline)
  • Plasma lipid concentrations: total cholesterol(Baseline)
  • Evaluation of oxidant burden: nitrotyrosine(Baseline)
  • Evaluation of carotid artery compliance(Baseline)
  • Evaluation of carotid artery beta stiffness index(Baseline)
  • Carotid artery intimal-medial thickness(Baseline)
  • Evaluation of oxidant burden: oxidized LDL(Baseline)
  • Appetite ratings(Baseline)
  • Evaluation of vascular endothelial cell inflammation: MCP-1(Baseline)
  • Evaluation of vascular endothelial cell inflammation: CRP(Baseline)
  • Insulin sensitivity(Baseline)
  • Whole body composition: Percent Lean Mass(Baseline)
  • Body weight(Baseline)
  • Depression symptoms(Baseline)
  • Physical activity monitoring(7 days)
  • Plasma lipid concentrations: triglycerides(Baseline)
  • Regional body composition: Percent Lean Mass(Baseline)
  • Evaluation of vascular endothelial cell inflammation: NFkB(Baseline)
  • Appetite-related peptides(Baseline)
  • D-Dimer(Baseline)
  • Regional body composition: Percent Fat Mass(Baseline)
  • Evaluation of vascular endothelial cell inflammation: IL-6(Baseline)
  • Blood pressure(Baseline)
  • Whole body composition: Percent Fat Mass(Baseline)
  • Energy intake(3 days)

Study Sites (1)

Loading locations...

Similar Trials